Pharming Nominates Robin Wright CFO
This article was originally published in Scrip
Executive Summary
Pharming Group, developer of hereditary angioedema therapy Ruconest (conestat alfa), has nominated Mr Robin Wright chief financial officer (CFO) and a member of its management board.